Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  European Journal of Pharmaceutical Sciences

• Publication date

  2002-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.EJPS.2003.09.007PMID 12356422
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Berichten

  2005cited by this paper
• New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR

  2004cited by this paper
• Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.

  2001cited by this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cited by this paper
• Effect of Ubidecarenone on Warfarin Anticoagulation and Pharmacokinetics of Warfarin Enantiomers in Rats

  2001cited by this paper
• Comparisons of the pharmacokinetics and the leukopenia and thrombocytopenia grade after administration of irinotecan and 5-fluorouracil in combination to rats.

  2000cited by this paper
• Warfarin—5‐FU Interaction — A Consecutive Case Series

  1999cited by this paper
• An Adverse Interaction between Warfarin and 5-Fluorouracil: A Case Report and Review of the Literature

  1999cited by this paper
• Accuracy of repeated blood sampling in rats: a new technique applied in pharmacokinetic/pharmacodynamic studies of the interaction between warfarin and co-enzyme Q10.

  1998cited by this paper
• Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

  1998cited by this paper
• Autoregulation of 5-fluorouracil metabolism.

  1998cited by this paper
• Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.

  1998cited by this paper
• Clinically Important Drug Interactions with Anticoagulants

  1996cited by this paper
• P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

  1996cited by this paper
• Modulation of the expression on constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil.

  1996cited by this paper
• Effect of Omeprazole on Diazepam Disposition in the Rat: in Vitro and in Vivo Studies

  1995cited by this paper
• Effects of 5-fluorouracil treatment on rat liver microsomal enzymes.

  1995cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer.

  1994cited by this paper
• Interactions of Warfarin with Drugs and Food

  1994cited by this paper
• Possible Drug Interaction between Warfarin and Combination of Levamisole and Fluorouracil

  1994cited by this paper
• Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model

  1994cited by this paper
• Effects of Diltiazem and Cimetidine on Theophylline Oxidative Metabolism

  1993cited by this paper
• Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics

  1993cited by this paper
• Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects

  1992cited by this paper
• The Influence of Diltiazem Versus Cimetidine on Propranolol Metabolism

  1992cited by this paper
• A study of the interaction of omeprazole and warfarin in anticoagulated patients.

  1992cited by this paper
• Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.

  1992cited by this paper
• Selective inhibition of warfarin metabolism by diltiazem in humans.

  1991cited by this paper
• Clinical Pharmacology of Omeprazole

  1991cited by this paper
• Omeprazole Drug Interaction Studies

  1991cited by this paper
• Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

  1990cited by this paper
• Clinical Pharmacology of 5-Fluorouracil

  1989cited by this paper
• Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men

  1989cited by this paper
• Effect of 5‐Fluorocytosine and 5‐Fluorouracil on Human and Rat Hepatic Cytochrome P 450 Die Wirkung von 5‐Fluorcytosin und 5‐Fluoruracil auf Leber‐Cytochrom‐P 450 in Mensch und Ratte

  1989cited by this paper
• The in vitro ketone reduction of warfarin and analogues. Substrate stereoselectivity, product stereoselectivity and species differences.

  1989cited by this paper
• Identification of two main urinary metabolites of [14C]omeprazole in humans.

  1989cited by this paper
• Microbial models of mammalian metabolism: conversion of warfarin to 4'-hydroxywarfarin using Cunninghamella bainieri.

  1989cited by this paper
• Characteristics of warfarin hydroxylation catalyzed by human liver microsomes.

  1989cited by this paper
• The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.

  1988cited by this paper
• Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

  1986cited by this paper
• Enzymes of uracil catabolism in normal and neoplastic human tissues.

  1985cited by this paper
• The Effect of Ranitidine and Cimetidine on Single‐dose Diltiazem Pharmacokinetics

  1985cited by this paper
• Pharmacokinetics and metabolism of omeprazole in animals and man--an overview.

  1985cited by this paper
• Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine.

  1984cited by this paper
• The Pharmacokinetic Basis for H2‐antagonist Drug Interactions: Concepts and Implications

  1983cited by this paper
• Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats.

  1983cited by this paper
• Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer.

  1982cited by this paper
• Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone.

  1982cited by this paper
• Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase

  1981cited by this paper
• Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man.

  1980cited by this paper
• Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition.

  1978cited by this paper
• Biochemical applications of a quantitative high-pressure liquid chromatographic assay of warfarin and its metabolites.

  1977cited by this paper
• Warfarin: stereochemical aspects of its metabolism in vivo in the rat.

  1976cited by this paper
• Enzyme kinetics: Behavior and analysis of rapid equilibrium and steady‐state enzyme systems. Author: Irwin H. Segal (University of California, Davis). Published by Wiley‐Interscience, New York, 1975. Price: $24.50. No. of pages: 957

  1976cited by this paper
• Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy.

  1974cited by this paper
• Effects of 5-fluorouracil on drug-metabolizing enzymes in the rat.

  1974cited by this paper
• Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

  1974cited by this paper
• Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

  1974cited by this paper
• Plasma half‐lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man *

  1973cited by this paper
• Studies on the 4-hydroxycoumarins. Synthesis of the metabolites and some other derivatives of warfarin.

  1971cited by this paper
• Drug metabolism after repeated treatments with cytotoxic agents.

  1971cited by this paper
• The effect of cytotoxic agents on drug metabolism.

  1970cited by this paper
• Mass spectral analysis in the identification of human metabolites of warfarin.

  1970cited by this paper
• Reduced Incidence of Spontaneous Metastases with Long‐Term Coumadin* Therapy

  1968cited by this paper
• Studies on the 4-Hydroxycoumarins. XVII.1a The Resolution and Absolute Configuration of Warfarin1b

  1961cited by this paper

• In vivo evaluation of pharmacokinetic drug–drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and capecitabin, and an anticoagulant, warfarin

  2022cites this paper
• A Study of Proton Pump Inhibitors and Other Risk Factors in Warfarin-Associated Gastrointestinal Bleeding

  2021cites this paper
• Development, Optimization, and In Vitro/In Vivo Characterization of Enhanced Lipid Nanoparticles for Ocular Delivery of Ofloxacin: the Influence of Pegylation and Chitosan Coating

  2019cites this paper
• RES-loaded pegylated CS NPs: for efficient ocular delivery.

  2017cites this paper
• Fluoropyrimidines S-1 and Capecitabine may Prolong International Normalized Ratios of Prothrombin Time by 3-Fold in Cancer Patients Receiving Warfarin

  2016cites this paper
• Validation and Application of a Simple UHPLC-MS-MS Method for the Enantiospecific Determination of Warfarin in Human Urine.

  2016cites this paper
• POSSO USAR A VARFARINA EM CONJUNTO COM OUTROS MEDICAMENTOS

  2015cites this paper
• Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats

  2012cites this paper
• Adverse Interaction between Capecitabine and Warfarin Resulting in Altered Coagulation Parameters: A Review of the Literature Starting from a Case Report

  2010cites this paper
• Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems

  2010cites this paper
• Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats

  2009cites this paper
• Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver.

  2009cites this paper
• PK/PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression

  2008cites this paper
• Mucoadhesive microdiscs engineered for ophthalmic drug delivery: effect of particle geometry and formulation on preocular residence time.

  2008cites this paper
• Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.

  2006cites this paper
• Drug interaction between capecitabine and warfarin: a case report and review of the literature.

  2006cites this paper
• Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance

  2006cites this paper
• An observational study examining the impact of capecitabine on warfarin antithrombotic activity and bleeding complications

  2006cites this paper
• Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5‐Fluorouracil Therapy

  2005cites this paper
• Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management.

  2005cites this paper
• Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-Fluorouracil-based chemotherapy?

  2004cites this paper
• Inhibitory effect of 5-fluorouracil on human cytochrome P450 isoforms in human liver microsomes

  2003influential citation